| Abstrakt: |
A recent study conducted by researchers at the University Hospital Erlangen in Germany examined the real-world treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in the USA, Europe, and Asia. The study analyzed data from the Ipsos Global Oncology Monitor database from 2018 to 2020 and found that the most common treatment for mHSPC patients was androgen deprivation therapy (ADT) monotherapy or a combination of first-generation androgen receptor inhibitors and ADT. The use of second-generation androgen receptor inhibitors was found to be increasing but still relatively low. The study also revealed that a significant percentage of mHSPC patients received non-guideline-concordant care, despite recommendations for treatment intensification. [Extracted from the article] |
